CXCL8 and neoplasm: In the context of erlotinib resistance, we demonstrated that blockade of IL-8 signaling via the use of a neutralizing antibody can revert mesenchymal tumor features and re-sensitize tumor cells to the cytotoxic effect of erlotinib.